Clinical Trial

Evaluating Omitting of Internal Mammary Irradiation Among Early Stage Intermediate Risk (N1) Breast Cancer

Recruiting
View on ClinicalTrials.gov →
Summary
The effect of internal mammary irradiation (IMI) added to whole-breast or thoracic-wall irradiation plus supraclavicular (SVC) irradiation after surgery on survival among women with early-stage intermediate risk (N1) breast cancer remains debated. The present study aimed to identified patient could be omitted from internal mammary lymph node irradiation by using a clinical-genomic model.
Protocol Amendment History 1 change
notable Primary completion pushed: 2025-10-30 -> 2027-10-30 2026-08-12
Trial Details
NCT Number NCT04517266
Lead Sponsor Ruijin Hospital
Conditions Breast Cancer
Enrollment 214 participants
Start Date 2021-03-01
Primary Completion 2027-10-30 (estimated)
Study Completion 2030-10-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-11